1
Country: USA | Funding: $624M
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
2
Country: USA | Funding: $237.5M
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
3
Country: USA | Funding: $198.8M
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
4
Country: Israel | Funding: $185M
Healthy.io de Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device. It’s the first smartphone-based urine test to secure clearance as a Class 2 device.
Healthy.io de Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device. It’s the first smartphone-based urine test to secure clearance as a Class 2 device.
5
Country: USA | Funding: $125.4M
Kalera Medical is the developer of a kidney stone retrieval device designed to remove kidney stone fragments. The company's device is vacuum-assisted that helps in extracting stones from a patient's kidney, enabling doctors to remove stone fragments completely, thereby addressing unmet medical needs.
Kalera Medical is the developer of a kidney stone retrieval device designed to remove kidney stone fragments. The company's device is vacuum-assisted that helps in extracting stones from a patient's kidney, enabling doctors to remove stone fragments completely, thereby addressing unmet medical needs.
6
Country: UK | Funding: $106.7M
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
7
Country: Sweden | Funding: $87.6M
OxThera is developing its Oxabact therapy that uses the O. formigenes bacteria to degrade oxalates in the intestines.
OxThera is developing its Oxabact therapy that uses the O. formigenes bacteria to degrade oxalates in the intestines.
8
Country: France | Funding: €81M
UroMems ambition is to offer to the patients suffering from severe urinary incontinence a simple and efficient innovative solution. UroMems is currently developing an active implantable medical device which compensates for sphincter insufficiency.
UroMems ambition is to offer to the patients suffering from severe urinary incontinence a simple and efficient innovative solution. UroMems is currently developing an active implantable medical device which compensates for sphincter insufficiency.
9
Country: USA | Funding: $51M
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
10
Country: USA | Funding: $29.1M
SonoMotion is developing non-invasive ultrasonic solutions for kidney stone disease. It allows to avoid surgical procedures by using long pulses of sound waves to push the smaller stones from the kidney safely and without anesthesia.
SonoMotion is developing non-invasive ultrasonic solutions for kidney stone disease. It allows to avoid surgical procedures by using long pulses of sound waves to push the smaller stones from the kidney safely and without anesthesia.
11
Country: UK | Funding: $19.1M
TestCard is the innovative medtech behind the 'urine test-in-a-postcard' concept. Its accompanying mobile app provides an immediate result.
TestCard is the innovative medtech behind the 'urine test-in-a-postcard' concept. Its accompanying mobile app provides an immediate result.
12
Country: USA | Funding: $19.3M
Image guided laser therapy for prostate cancer in a doctor’s office.
Image guided laser therapy for prostate cancer in a doctor’s office.
13
Country: Spain | Funding: $11.6M
Devicare has developed Lit-Control - the most advanced, comprehensive and effective medical treatment for Kidney Stones. Lit-Control is a family of four innovative medical foods that have been formulated to treat and manage the nutritional needs of patients with each of the four major groups of Kidney Stones (i.e. calcium, uric acid, infectious and cytine stones). And in combination with these medical foods, Lit-Control also incorporates a ground-breaking digital therapeutic to ease the follow-up of these patients.
Devicare has developed Lit-Control - the most advanced, comprehensive and effective medical treatment for Kidney Stones. Lit-Control is a family of four innovative medical foods that have been formulated to treat and manage the nutritional needs of patients with each of the four major groups of Kidney Stones (i.e. calcium, uric acid, infectious and cytine stones). And in combination with these medical foods, Lit-Control also incorporates a ground-breaking digital therapeutic to ease the follow-up of these patients.
14
Country: Belgium | Funding: $9.4M
Minze Health enables better care for billion people with Lower Urinary Tract Symptoms (LUTS).
Minze Health enables better care for billion people with Lower Urinary Tract Symptoms (LUTS).
15
Country: USA | Funding: $9.1M
Butterfly has designed an anatomically shaped nitinol implant, which is positioned in the prostatic urethra in order to open the space and relieve BPH symptoms. The device comes in multiple sizes, and, unlike more invasive approaches, does not require any resection, cutting, or burning of prostatic tissue. The procedure can be completed in under six minutes in the urologist’s office.
Butterfly has designed an anatomically shaped nitinol implant, which is positioned in the prostatic urethra in order to open the space and relieve BPH symptoms. The device comes in multiple sizes, and, unlike more invasive approaches, does not require any resection, cutting, or burning of prostatic tissue. The procedure can be completed in under six minutes in the urologist’s office.
16
Country: USA | Funding: $3.8M
Oxalo Therapeutics develops a first-of-its-kind peptide-based drug to prevent kidney stones.
Oxalo Therapeutics develops a first-of-its-kind peptide-based drug to prevent kidney stones.
17
Country: Poland | Funding: $2.7M
DEBN has developed an innovative prostate biopsy needle for urologists that reduces the incidence of infectious complications by delivering an optimal combination of antibiotics directly into the prostate, precisely where infections can occur. The device consists of a polymer-coated biopsy needle and an anesthetic needle, which release the drug directly into the prostate during the procedure. The very first DEBN model used polyvinyl alcohol and amikacin.
DEBN has developed an innovative prostate biopsy needle for urologists that reduces the incidence of infectious complications by delivering an optimal combination of antibiotics directly into the prostate, precisely where infections can occur. The device consists of a polymer-coated biopsy needle and an anesthetic needle, which release the drug directly into the prostate during the procedure. The very first DEBN model used polyvinyl alcohol and amikacin.
18
Country: USA
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
19
Country: UAE
ProvenMed have developed the revolutionary ActivGo for men - the first urinary incontinence wearable device
ProvenMed have developed the revolutionary ActivGo for men - the first urinary incontinence wearable device
